U.S. NeuroSurgical (USNU) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 27, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	U.S. NeuroSurgical Holdings, Inc.
Entity Central Index Key	1,089,815
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		7,797,185
Entity Public Float			$ 771,000
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,068,000	$ 1,053,000
Accounts receivable	626,000	277,000
Due from related parties	21,000	8,000
Elekta refund due	0	115,000
Short term loan receivable	35,000	0
Other current assets	98,000	72,000
Total current assets	1,848,000	1,525,000
Other assets:
Notes receivable	210,000	0
Investment in unconsolidated entities	364,000	323,000
Total other assets	574,000	323,000
Property and equipment:
Gamma knife (net of accumulated depreciation of $1,097,000 in 2015 and $475,000 in 2014)	3,294,000	3,960,000
Leasehold improvements (net of accumulated amortization of $510,000 in 2015 and $197,000 in 2014)	1,670,000	1,643,000
Total property and equipment	4,964,000	5,603,000
TOTAL ASSETS	7,386,000	7,451,000
Current liabilities:
Obligations under capital lease - current portion	866,000	821,000
Deferred tax liability- current portion	191,000	92,000
Accounts payable and accrued expenses	80,000	96,000
Deferred revenue	149,000	48,000
Due to related parties	13,000	13,000
Total current liabilities	1,299,000	1,070,000
Obligations under capital lease - net of current portion	2,945,000	3,838,000
Deferred tax liability - net of current portion	303,000	150,000
Guarantee liability	15,000	0
Asset retirement obligations	466,000	431,000
Total liabilities	5,028,000	5,489,000
STOCKHOLDERS' EQUITY
Common stock - par value $.01; 25,000,000 shares authorized; 7,797,185 shares issued and outstanding at December 31, 2015 and 2014	78,000	78,000
Additional paid-in capital	3,100,000	3,100,000
Accumulated deficit	(820,000)	(1,216,000)
Total stockholders' equity	2,358,000	1,962,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 7,386,000	$ 7,451,000

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property and equipment:
Gamma knife, accumulated depreciation	$ 1,097,000	$ 475,000
Leasehold improvement, accumulated depreciation	$ 510,000	$ 197,000
STOCKHOLDERS' EQUITY
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	7,797,185	7,797,185
Common stock, shares outstanding (in shares)	7,797,185	7,797,185

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 2,971,000	$ 2,607,000
Costs and expenses:
Patient expenses	1,195,000	692,000
Selling, general and administrative	1,232,000	1,179,000
Total	2,427,000	1,871,000
Operating income	544,000	736,000
Interest expense	(181,000)	(184,000)
Gain from sales of investments in unconsolidated entities	0	237,000
Income from investments in unconsolidated entities	285,000	14,000
Income before income taxes	648,000	803,000
Provision for income tax expense	(252,000)	(242,000)
Net income	$ 396,000	$ 561,000
Basic and diluted net income per share (in dollars per share)	$ 0.05	$ 0.07
Weighted average common shares outstanding (in shares)	7,797,185	7,797,185

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 78,000	$ 3,100,000	$ (1,777,000)	$ 1,401,000
Balance (in shares) at Dec. 31, 2013	7,797,185
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 0	0	561,000	561,000
Balance at Dec. 31, 2014	$ 78,000	3,100,000	(1,216,000)	$ 1,962,000
Balance (in shares) at Dec. 31, 2014	7,797,185			7,797,185
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 0	0	396,000	$ 396,000
Balance at Dec. 31, 2015	$ 78,000	$ 3,100,000	$ (820,000)	$ 2,358,000
Balance (in shares) at Dec. 31, 2015	7,797,185			7,797,185

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income	$ 396,000	$ 561,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	935,000	672,000
Income from investment in unconsolidated entities, net	(285,000)	(14,000)
Gain from sales of investments in unconsolidated entities	0	(237,000)
Accretion of asset retirement obligations	35,000	0
Accrued interest from capital lease obligations	(42,000)	56,000
Deferred income taxes	252,000	242,000
Changes in:
Accounts receivable	(349,000)	(277,000)
Elekta refund due	115,000	0
Other current assets	(26,000)	(42,000)
Accounts payable and accrued expenses	26,000	(58,000)
Deferred revenue	101,000	48,000
Net cash provided by operating activities	1,158,000	951,000
Cash flows from investing activities:
Distributions from unconsolidated entities	312,000	0
Proceeds from sale of investments	0	256,000
Advances - short term receivable and note receivable	(245,000)	0
Purchase of leasehold improvements	(341,000)	(1,541,000)
Investments in unconsolidated entities	(6,000)	0
(Increase in) decrease of due from related parties	(60,000)	313,000
Net cash used in investing activities	(340,000)	(972,000)
Cash flows from financing activities:
Repayment of capital lease obligations	(803,000)	(340,000)
Repayment of short-term loans	0	(462,000)
Proceeds from short-term loans	0	462,000
Net cash used in financing activities	(803,000)	(340,000)
Net change in cash and cash equivalents	15,000	(361,000)
Cash and cash equivalents - beginning of year	1,053,000	1,414,000
Cash and cash equivalents - end of year	1,068,000	1,053,000
Cash paid for:
Interest	189,000	128,000
Supplemental disclosure of noncash investing and financing activities:
Increase in guarantee liability recorded	15,000	0
Purchase of gamma knife and related leasehold improvements through capital lease obligation	0	1,354,000
Increase in fixed assets due to capitalization of asset retirement obligation	0	431,000
Elekta refund due financed by capital lease obligation	$ 0	$ 115,000

Organization and Business

Organization and Business	12 Months Ended
	Dec. 31, 2015
Organization and Business [Abstract]
Organization and Business	Note A – Organization and Business U.S. NeuroSurgical Holdings, Inc. owns and operates, through its wholly-owned subsidiaries, stereotactic radiosurgery centers, utilizing gamma knife technology, and holds other interests in radiological treatment facilities. As used herein, unless the context indicates otherwise, the term "Company", "Registrant" and "Holdings" means U.S. NeuroSurgical Holdings, Inc. and its wholly-owned subsidiary, U.S. NeuroSurgical, Inc. (“USN”), and the wholly-owned subsidiaries of USN, U.S. NeuroSurgical Physics, Inc. and USN Corona, Inc. U.S. NeuroSurgical, Inc. a Delaware corporation, was organized in July 1993 for the purpose of owning and operating stereotactic radiosurgery centers, utilizing the gamma knife technology. USN owns one gamma knife center on the premises of New York University Medical Center (“NYU”) in New York, New York. Management continues to explore opportunities to organize and participate in additional gamma knife centers. USN's business strategy is to provide a mechanism whereby hospitals, physicians, and patients can have access to gamma knife treatment capability, a high capital cost item. USN provides the gamma knife to medical facilities on a "cost per treatment" basis. USN holds an interest in the gamma knife unit, and is reimbursed by the facility where it is housed, based on utilization. During the fourth quarter of 2007, USN formed a wholly-owned subsidiary, USN Corona, Inc. (“USNC”), to carry investments in Corona Gamma Knife, LLC and NeuroPartners, LLC. Those investments were formed to develop and manage a gamma knife center at San Antonio Regional Hospital in Upland, California. (See Note C[1]) During 2010, USN expanded its market strategy to include opportunities to develop cancer centers featuring radiation therapy. These centers utilize linear accelerators with IMRT (Intensity Modulated Radiation Therapy) and IGRT (Image Guided Radiation Therapy) capabilities. In 2010, the Company formed Florida Oncology Partners, LLC in partnership with local physicians and other investors. USNC owns a 24% interest in the venture. The center is located in Miami and opened in the second quarter of 2011. (See Note C[2]) In 2011, the Company formed Boca Oncology Partners, LLC in partnership with local physicians and other investors. USNC initially owned a 22.5% interest in the venture. Following a sale of 50% of the Company’s interest in 2012 the Company’s interest in Boca Oncology Partners decreased to 11.25%. The center is located in Boca Raton, Florida, and was opened in the third quarter of 2012. In February 2014, the Company and other members sold their interests in Boca Oncology Partners, LLC. (See Note C[3]) In early 2013, the Company formed Broward Oncology Partners, LLC (“BROP”) with other outside investors. The Company invested $50,000 for a 12.5% ownership interest in BROP. BROP operates a radiation oncology center in Fort Lauderdale, Florida under a lease from Tenet Health Services. BROP began operations in February 2013. In May 2014, the Company and other members sold their interests in BROP. (See Note C[4]) On October 29, 2012, the Company’s facility at NYU was totally destroyed as a result of flooding from Hurricane Sandy. During 2014, the Company finalized arrangements with NYU regarding the restoration of the gamma knife center and the Company’s long term contract with NYU. The location of the restored facility, with the new Leksell PERFEXION gamma knife, is in the Tisch Hospital of NYU Langone Medical Center. The center reopened, and the first patient was treated on April, 29, 2014. (See Note D) On September 3, 2015, pursuant to the Agreement and Plan of Reorganization (the “Merger Agreement”), dated as of September 3, 2015, by and among U.S. NeuroSurgical, Inc., U.S. NeuroSurgical Holdings, Inc. (“Holdings”) and U.S. NeuroSurgical Merger Sub, Inc. (“Merger Sub”), the Company adopted a new holding company organizational structure whereby USN is now a wholly owned subsidiary of Holdings. This structure did not result in any changes to the assets or operations of the Company, but management believes that it will create a more flexible framework for possible future transactions and organizational and operational adjustments. The holding company organizational structure was effected by a merger (the “Merger”) conducted pursuant to Section 251(g) of the Delaware General Corporation Law (the “DGCL”), which provides for the formation of a holding company structure without a vote of the stockholders of the constituent corporations. Because the holding company organizational structure occurred at the parent company level, the remainder of the Company’s subsidiaries, operations and customers were not affected by this transaction. In order to effect the Merger, USN formed Holdings as its wholly owned subsidiary and Holdings formed Merger Sub as its wholly owned subsidiary. Under the terms of the Merger Agreement, Merger Sub merged with and into USN, with USN surviving the merger and becoming a direct, wholly owned subsidiary of Holdings. Immediately prior to the Merger, Holdings had no assets, liabilities or operations. Pursuant to the Merger Agreement, all of the outstanding capital stock of USN was converted, on a share for share basis, into capital stock of Holdings. As a result, each former stockholder of USN became the owner of an identical number of shares of capital stock of Holdings, evidencing the same proportional interests in Holdings and having the same designations, rights, powers and preferences, qualifications, limitations and restrictions, as those that the stockholder held in USN. Following the Merger, Holdings’ common stock continued to trade on the over-the-counter market and continued to be quoted on the OTCQB marketplace under the same symbol, “USNU.” The conversion of shares of capital stock under the Merger Agreement occurred without an exchange of physical certificates. Accordingly, physical certificates formerly representing shares of outstanding capital stock of USN are deemed to represent the same number of shares of capital stock of Holdings. Pursuant to Section 251(g) of the DGCL, the provisions of the certificate of incorporation and bylaws of Holdings are substantially identical to those of USN prior to the date on which the Merger Agreement took effect. The authorized capital stock of Holdings, the designations, rights, powers and preferences of such capital stock, and the qualifications, limitations and restrictions thereof are also substantially identical to those of the capital stock of USN immediately prior to the date of the Merger. Further, the directors and executive officers of Holdings are the same individuals who were directors and executive officers, respectively, of USN immediately prior to the date of the Merger.

The Company and its Significant

The Company and its Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
The Company and its Significant Accounting Policies [Abstract]
The Company and its Significant Accounting Policies	Note B - The Company and its Significant Accounting Policies [1] Basis of presentation and consolidation: The consolidated financial statements include the accounts of Holdings and its wholly-owned subsidiaries, USN, USNC and US NeuroSurgical Physics, Inc.. All significant intercompany balances and transactions have been eliminated in consolidation. [2] Cash and cash equivalents: The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. [3] Investments in unconsolidated entities: The Company accounts for its investments in unconsolidated entities by the equity method. The Company records its share of such earnings (loss) in the Consolidated Statement of Operations as “Income (loss) from investments in unconsolidated entities”. The carrying value of the Company’s investments in unconsolidated entities is recorded in the Consolidated Balance Sheets. The Company records losses of the unconsolidated entities only to the extent of the Company’s interest in and advances to the entities. As such, the recorded balance of Corona Gamma Knife, LLC and NeuroPartners, LLC have been taken to zero. [4] Revenue recognition: The Company’s agreement with NYU is an operating lease, and patient revenue from the use of the gamma knife is lease income. There are no minimum lease payments from NYU. The NYU agreement provides for contingent rental income based on a tiered fee schedule related to the number of patient procedures and associated thresholds. The Company recognizes the contingent rental income on a systematic basis using an average fee per procedure calculated by estimating the expected number of procedures per contract year which runs from November 1, to the following October 31. Any amounts received in excess of the average fee are considered deferred revenue. At the end of each reporting period, the Company reviews its estimated revenue for the contract year and adjusts revenue for any material changes in the estimate. At the end of the contract year, the revenue is adjusted to the actual amount received. [5] Long-lived assets: The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. [6] Depreciation and amortization: The gamma knife is being depreciated on the straight-line method over an estimated useful life of 7 years. Leasehold improvements are being amortized on the straight-line method over 7 years, the shorter of useful life, or the life of the NYU Agreement. Office furniture and computers are being depreciated on the straight-line method over their estimated useful lives ranging from 3 to 7 years. Depreciation expense for 2015 and 2014 was $622,000 and $475,000 respectively. Amortization expense for 2015 and 2014 was $313,000 and $197,000 respectively. [7] Capital leases: Capital lease obligations are amortized ratably over the original term of the lease agreement, beginning with the earlier of the date the leased assets are placed in service or the effective date of the lease as defined in the lease agreement. [8] Guarantees: The Company recognizes a liability at the fair value of the obligation at the inception of a financial guarantee contract. The initial liability is subsequently reduced as the Company is released from exposure under the guarantee. If it becomes probable that the Company will have to perform on a guarantee, a separate liability is accrued if it is reasonably estimable, based on the facts and circumstances at that time. The Company reverses the fair value liability only when there is no further exposure under the guarantee. [9] Income taxes: Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce tax assets to amounts more likely than not to be realized. The Company has adopted the accounting provisions for Accounting for Uncertainty in Income Taxes [10] Earnings per share: Earnings per share are computed by dividing earnings available to common stockholders by the weighted average shares outstanding for the period. There were no common stock equivalents during 2015 and 2014, and therefore, no potential dilution for the periods presented. [11] Advertising costs: The Company follows the policy of charging the costs of advertising to expense as incurred. There were no advertising costs in 2015 and 2014. [12] Allowance for doubtful accounts: The Company evaluates each of its accounts receivable individually and provides a charge to income that is appropriate, in the opinion of management, to absorb probable credit losses. The Company considers all accounts receivable to be collectible at December 31, 2015 and 2014. [13] Estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. [14] Fair values of financial instruments: The estimated fair value of financial instruments has been determined based on available market information and appropriate valuation methodologies. The carrying amounts of cash and cash equivalents, accounts receivable, other current assets, due from or to related parties, and accounts payable approximate fair value at December 31, 2015 and 2014 because of the short maturity of these financial instruments. The carrying values of the notes receivable and the obligations under capital leases, approximate fair value because the interest rates on these instruments approximate the market rates at December 31, 2015 and 2014. [15] Credit risk: At times, the Company may have cash and cash equivalents at a financial institution in excess of insured limits. The Company places its cash and cash equivalents with high credit quality financial institutions whose credit ratings are monitored by management to minimize credit risk. Accounts receivable consist primarily of amounts due from the medical centers. Historically, credit losses on accounts receivable have not been significant. At December 31, 2015 and 2014, substantially all of the Company’s accounts receivable were due from one customer, NYU. [16] Asset retirement obligations: The Company records liabilities for legal obligations associated with the retirement of tangible long-lived assets based on the estimated future cost of asset retirement obligations discounted to present value, and records a corresponding asset and liability on its consolidated balance sheets. The values ultimately derived are based on many significant estimates, including future decommissioning costs, inflation, cost of capital, and market risk premiums. The nature of these estimates requires the Company to make judgments based on historical experience and future expectations. Revisions to the estimates may be required based on such things as changes to cost estimates or the timing of future cash outlays. Any such changes that result in upward or downward revisions in the estimated obligation will result in an adjustment to the related capitalized asset and corresponding liability on a prospective basis.

Investment in Unconsolidated En

Investment in Unconsolidated Entities	12 Months Ended
	Dec. 31, 2015
Investment in Unconsolidated Entities [Abstract]
Investment in Unconsolidated Entities	Note C - Investment in Unconsolidated Entities [1] The Southern California Regional Gamma Knife Center During 2007, the Company managed the formation of the Southern California Regional Gamma Knife Center at San Antonio Regional Hospital (“SARH”) in Upland, California. The Company participates in the ownership and operation of the center through USNC. Corona Gamma Knife, LLC (“CGK”) is party to a 14-year agreement with SARH to renovate space in the hospital and install and operate a Leksell PERFEXION gamma knife. CGK leased the gamma knife from NeuroPartners LLC, which holds the gamma knife equipment. In addition to returns on its ownership interests, USNC expects to receive fees for management services relating to the facility. USNC is a 20% owner of NeuroPartners LLC. USNC also owned initially 27% of CGK, but increased its ownership to 44% during 2011 to accommodate a member who desired to transfer his interest. Subsequently, in the first quarter of 2012, USNC sold a portion of its ownership to a new member, resulting in a decrease in its ownership in CGK to 39%. Construction of the SARH gamma knife center was completed in December 2008 and the first patient was treated in January 2009. The project has been funded principally by outside investors. While the Company has led the effort in organizing the business and overseeing the development and operation of the SARH center, its investment to date in the SARH center has been minimal. The Company’s share of cumulative losses associated with its investment in NeuroPartners LLC and CGK has exceeded its investment. Due to the outstanding loans made to NeuroPartners LLC and CGK, NeuroPartners LLC and CGK are considered to be variable interest entities of the Company. However, as the Company is not deemed to be the primary beneficiary of NeuroPartners LLC and CGK, since it does not have the power to direct the operating activities that most significantly affect NeuroPartners LLC’s and CGK’s economic performance; certain disclosures are required rather than consolidation. During 2015 and 2014, the Company absorbed losses against the total outstanding receivables from NeuroPartners LLC and CGK of $62,000 and $45,000, respectively, due to these losses. The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK: Neuro Partners LLC and CGK Combined Condensed Income Statement Information Year Ended December 31, 2015 2014 Patient revenue $ 912,000 $ 1,223,000 Net (loss) income $ (184,000 ) $ 74,000 USNC's equity in (loss) income of Neuro Partners LLC and CGK $ (84,000 ) $ 14,000 Neuro Partners LLC and CGK Combined Condensed Balance Sheet Information December 31, 2015 2014 Current assets $ 66,000 $ 92,000 Noncurrent assets 394,000 991,000 Total assets $ 460,000 $ 1,083,000 Current liabilities $ 1,359,000 $ 829,000 Noncurrent liabilities - 969,000 Equity (899,000 ) (715,000 ) Total liabilities and equity $ 460,000 $ 1,083,000 [2] Florida Oncology Partners During the quarter ended September 30, 2010, the Company participated in the formation of Florida Oncology Partners, LLC (“FOP”) and Florida Oncology Partners RE, LLC (“FOPRE”), which operates a cancer center located in West Kendall (Miami), Florida. The center diagnoses and treats patients utilizing a Varian Rapid Arc linear accelerator and a GE CT scanner. USNC originally invested $200,000 for 20% ownership interest in FOP and FOPRE, increasing its investment to 24% in January of 2015 when another investor’s shares were diluted. The remaining 76% is owned by other outside investors. The center opened and treated its first patient in May 2011. During 2013, FOP made several distributions that reduced the Company’s investment significantly. The Company’s investment in FOP and FOPRE is $225,000 and $190,000 at December 31, 2015 and 2014. Amounts due from FOP and FOPRE included in due from related parties total $21,000 and $8,000 at December 31, 2015 and 2014, respectively. During 2015, FOPRE sold the building it owned and recognized a gain of $577,000. The following tables present the aggregation of summarized financial information of FOP and FOPRE: FOP and FOPRE Combined Condensed Income Statement Information Year Ended December 31, 2015 2014 Revenue $ 3,157,000 $ 2,631,000 Net income $ 1,344,000 $ 197,000 USNC's equity in income of FOP and FOPRE $ 323,000 $ 39,000 FOP and FOPRE Combined Condensed Balance Sheet Information December 31, 2015 2014 Current assets $ 1,024,000 $ 606,000 Noncurrent assets 3,066,000 5,070,000 Total assets $ 4,090,000 $ 5,676,000 Current liabilities $ 1,848,000 $ 858,000 Noncurrent liabilities 1,529,000 3,947,000 Equity 713,000 871,000 Total liabilities and equity $ 4,090,000 $ 5,676,000 [3] Boca Oncology Partners During the quarter ended June 30, 2011, the Company participated in the formation of Boca Oncology Partners, LLC (“BOP”), for the purpose of owning and operating a cancer center in Boca Raton, Florida. In June 2011, Boca Oncology Partners RE, LLC (“BOPRE”), an affiliated entity, purchased a 20% interest in Boca West IMP, LLC (“Boca West IMP”), owner of a medical office building in West Boca, Florida in which In January 2012, an additional investor purchased 50% of the partnership reducing the Company’s ownership to 11.25%. The Company loaned the proceeds of $56,250 back to BOP as a 5 year note at 7% interest. The remaining 88.75% was owned by other outside investors. In June 2012, BOPRE purchased an additional 3.75% of Boca West IMP from another investor bringing its total interest to 23.75%. BOPRE accounts for this investment under the cost method since it does not exercise significant influence over Boca West, IMP. Then the members of BOPRE sold 31.5% of their interests in BOPRE to a new investor. The proceeds of $28,000 were loaned to BOP and USNC’s investment in BOPRE was reduced to 15.4%. Although the Company reduced its investment to 11.25% of BOP and 15.4% of BOPRE, the Company continues to account for these investments under the equity method due to its participation in the management of the administration and accounting functions of BOP and BOPRE. Due to the outstanding loans made to BOP, BOP was considered to be a variable interest entity of the Company. However, as the Company was not deemed to be the primary beneficiary of BOP, since it did not have the power to direct the operating activities that most significantly affect BOP’s economic performance; certain disclosures are required rather than consolidation. The center opened in August 2012. Since June 2012, the Company’s share of cumulative losses associated with its investment in BOP has exceeded its investment. The Company’s recorded investment in BOPRE is $139,000 and $134,000 at December 31, 2015 and 2014. In February 2014, the Company and other members sold their interests in BOP, resulting in a gain of $204,000. Three members provided short-term loans to the Company of $462,000 from their sales proceeds. The Company had accrued $26,000 in interest expense related to these loans. During the year ended December 31, 2014, the Company repaid all of the loan balance and related interest. The following tables present the summarized financial information of BOP and BOPRE: BOP Condensed Income Statement Information Year Ended December 31, 2014 Patient revenue $ 115,000 Net loss $ (108,000 ) USNC's equity in loss $ (12,000 ) BOPRE Condensed Income Statement Information Years Ended December 31, 2015 2014 Rental Income $ 3,000 $ - Net income (loss) $ 3,000 $ (4,000 ) USNC's equity in loss $ - $ - BOPRE Condensed Balance Sheet Information December 31, 2015 2014 Current assets $ 40,000 $ 61,000 Noncurrent assets 837,000 786,000 Total assets $ 877,000 $ 847,000 Current liabilities $ - $ - Noncurrent liabilities - - Equity 877,000 847,000 Total liabilities and equity $ 877,000 $ 847,000 [4] Broward Oncology Partners In early 2013, the Company formed Broward Oncology Partners, LLC (“BROP”) with other outside investors. The Company invested $50,000 for a 12.5% ownership interest in BROP. BROP operates a radiation oncology center in Fort Lauderdale, Florida under a lease from Tenet Health Services. BROP began operations in February 2013. In May 2014, the Company and other members sold their interests in BROP, resulting in a gain of $33,000. Broward Oncology Partners, LLC Condensed Income Statement Information Year Ended December 31, Patient revenue $ 505,000 Net income (loss) $ 255,000 USNC's equity in income (loss) of Broward Oncology Partners $ 32,000

Agreement with New York Univers

Agreement with New York University on Behalf of New York University Medical Center (NYU)	12 Months Ended
	Dec. 31, 2015
Agreement With New York University on Behalf of New York University Medical Center (NYU) [Abstract]
Agreement with New York University on Behalf of New York University Medical Center (NYU)	Note D - Agreement with New York University on Behalf of New York University Medical Center (NYU) During November 1996, USN entered into a neuroradiosurgery equipment agreement (the “NYU agreement”) with NYU for a period of seven years (the “term”), with an option for NYU to extend the term for successive three-year periods or to purchase the gamma knife equipment at an appraised market value price. USN had the ability to negotiate the purchase price and upon failure of the parties to agree could request that the facility be closed. All costs associated with closing and restoring the facility to its original condition are the responsibility of USN. The NYU agreement, among other matters, required USN to provide (i) the use of the gamma knife equipment to NYU, (ii) training necessary for the proper operation of the gamma knife equipment, (iii) sufficient supplies for the equipment, (iv) the repair and maintenance of the equipment, (v) all basic hardware and software upgrades to the equipment and, (vi) an uptime guarantee. In return, NYU paid USN a scheduled fee based on the number of patient procedures performed. The Company derived patient revenue from the NYU center of $2,944,000 and $2,607,000, for 2015 and 2014 respectively. The NYU agreement is accounted for as an operating lease. In 2004, the NYU agreement was extended through March 2009. In 2008, the NYU agreement was extended for an additional 12 years through March 2021. To secure this extension, USN agreed to install a new gamma knife PERFEXION model. The new equipment and certain space improvements, costing approximately $3,742,000 in total, was financed through a seven-year lease arrangement. The amendment provides for a payment to USN of a flat fee for each patient procedure performed. In October 2012, the Company’s facility at NYU was totally destroyed as a result of flooding from Hurricane Sandy. The gamma knife had to be removed to prevent any cobalt leakage that might occur due to rusting of the equipment. The removal cost was $525,000. The Company paid a lease settlement of the outstanding principal balance only and received from insurance coverage $930,000 above the lease principal payments and emergency removal costs. The Company finalized arrangements with NYU regarding the restored gamma knife center and the Company’s long term contract with NYU. The Company’s new facility, with the Leksell PERFEXION gamma knife, is located in the Tisch Hospital of NYU Langone Medical Center. The facility reopened and began receiving patients at the end of April 2014. The Company entered into a six year lease in the amount of $4.7 million for the purchase of the replacement equipment and associated leasehold improvements. The first payment of $78,000 was made on September 1, 2014, including $18,000 of interest, and the final payment is due on May 1, 2020. The Company entered into a second two year lease in the amount of $250,000 for the cost of the construction required at the relocated site. The first payment of $12,000 was made on November 1, 2014, and the final payment is due on July 1, 2016. The major terms of the agreement with NYU continue in effect, terminating at the end of March 2021. The Company is responsible for the maintenance and insurance for the gamma knife equipment at the NYU facility and is reimbursed for use of the gamma knife based on a fee per procedure performed with the equipment. NYU provides the medical and technical staff to operate the facility. At the end of the contract term, costs associated with closing and restoring the NYU facility to its original condition are the responsibility of USN.

Obligation Under Capital Lease

Obligation Under Capital Lease	12 Months Ended
	Dec. 31, 2015
Obligation Under Capital Lease [Abstract]
Obligation Under Capital Lease	Note E - Obligation Under Capital Lease In March 2009, the Company installed a PERFEXION model gamma knife at the NYU center with a seven year lease from Elekta Capital. The amount financed, covering the cost of the new gamma knife equipment and certain space improvements, was approximately $3,742,000 in total. The monthly payment was $63,000 per month, at an implicit interest rate of approximately 11%. This lease became payable as a result of the damage at the NYU facility in October 2012, and the remainder of the balance due was paid in January 2013. In 2013, the Company entered into a modification of the above capital lease agreement to finance the new gamma knife installation and related construction costs and the removal costs of the old equipment for approximately $4.7 million to be repaid over 72 months with no payments for the first three months. The remaining removal costs of the old equipment of $525,000 were reclassified to the capital lease obligation at December 31, 2013 since they were paid by Elekta Capital (Note F). The Company entered into another capital lease in 2014 to finance a further $250,000 of installation and construction costs. The balance is being repaid over 24 months with the final payment due April 2016. The obligations under the capital leases are as follows: December 31, 2015 2014 Capital leases - Gamma Knife $ 3,811,000 $ 4,659,000 Less current portion (866,000 ) (821,000 ) $ 2,945,000 $ 3,838,000 The following is an analysis of the leased assets included in property and equipment: December 31, 2015 2014 Capitalized costs $ 4,303,000 $ 4,303,000 Less - accumulated depreciation (1,076,000 ) (461,000 ) Capitalized lease equipment and improvements- reported as property and equipment - net $ 3,227,000 $ 3,842,000 Depreciation expense for assets under capital leases totaled $615,000 and $461,000 for the years ended December 31, 2015 and 2014. During the year ended December 31, 2014, $51,000 of interest was capitalized. Future payments as of December 31, 2015 on the equipment leases and loans are as follows: Year Ending December 31, 2016 $ 1,019,000 2017 931,000 2018 931,000 2019 931,000 2020 388,000 4,200,000 Less interest (389,000 ) Present value of net minimum obligation $ 3,811,000

Asset Retirement Obligations

Asset Retirement Obligations	12 Months Ended
	Dec. 31, 2015
Asset Retirement Obligations [Abstract]
Asset Retirement Obligations	Note F – Asset Retirement Obligations When the NYU agreement was finalized, the Company estimated the cost to remove the gamma knife at the end of the agreement to be approximately $620,000. The estimated present value of this liability is $466,000 at December 31, 2015 and $431,000 at December 31, 2014. 2015 2014 Asset retirement obligations, start of year $ 431,000 $ - Asset retirement obligation for new gamma knife 431,000 Accretion of liability 35,000 - Asset retirement of obligations, end of the year $ 466,000 $ 431,000

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2015
Concentrations [Abstract]
Concentrations	Note G - Concentrations The Company derives substantially all of its revenue from NYU. Due to the destruction of the gamma knife at NYU the Company received no revenue from January 1, 2014 through April 28, 2014. The new location, of the Leksell PERFEXION gamma knife in the Tisch Hospital of NYU Langone Medical Center, opened and treated its first patient on April, 29, 2014. (See Note D)

Taxes

Taxes	12 Months Ended
	Dec. 31, 2015
Taxes [Abstract]
Taxes	Note H – Taxes A reconciliation of the tax provision calculated at the statutory federal income tax rate with amounts reported follows: Year Ended December 31, 2015 2014 Income tax at the federal statutory rate $ 220,000 $ 273,000 State income tax, net of federal taxes 21,000 26,000 Permanent differences 14,000 11,000 Other (3,000 ) (16,000 ) Change in valuation allowance - (52,000 ) Income tax (benefit) provision $ 252,000 $ 242,000 Items which give rise to deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax asset: Net operating loss $ 463,000 $ 667,000 Basis difference in unconsolidated entities 32,000 - 495,000 667,000 Deferred tax liability: Basis difference in unconsolidated entities - (61,000 ) Deferred gain on disposal of gamma knife (716,000 ) (716,000 ) Excess of depreciation over book depreciation (82,000 ) (40,000 ) Net effect of conversion from the accrual basis of accounting to the cash basis of accounting for tax purposes primarily related to accounts receivable, prepaid expense, deferred revenue, and accounts payable (191,000 ) (92,000 ) Net deferred tax liability $ (494,000 ) $ (242,000 ) At December 31, 2015, the Company had loss carryforwards of $1,239,000, which may be offset against future taxable income. If not used, the carryforwards will begin to expire in 2025. The Company files income tax returns in the U.S. federal jurisdiction and the State of Maryland. With few possible exceptions, the Company is no longer subject to U.S. or state income tax examinations by tax authorities for years before 2012.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note I– Commitments and Contingencies [1] Leases: The Company leases office space under an operating lease which was renewed in March 2013, and expires March 2018. The terms of the lease include an escalation clause for a portion of certain operating expenses. At December 31, 2015, the annual future minimum rental payments under operating leases are as follows: Year Ending December 31, 2016 $ 42,000 2017 43,000 2018 11,000 $ 96,000 Rent expense was approximately $41,000 and $43,000 for 2015 and 2014, respectively. [2] Gamma Knives: In 2009, the Company installed a new gamma knife PERFEXION model at the NYU Medical Center. This new equipment and certain space improvements, costing approximately $3,742,000 in total, were financed through a seven-year lease arrangement. This PERFEXION equipment was recorded as a total loss as a result of flooding from Hurricane Sandy. See Notes D and E. In early 2014, the Company entered into a six year lease in the amount of $4.7 million for the purchase of the replacement equipment and associated leasehold improvements. The first payment of $78,000 was made on September 1, 2014, including $18,000 of interest, and the final payment is due on May 1, 2020. The Company entered into a second capital lease in 2014 to finance an additional $250,000 of installation and construction costs. The first payment of $12,468 was made November 1, 2014. The final payment is due on July 1, 2016. To maintain efficient operation, the Company is required to reload cobalt for each gamma knife every 5 to 10 years. [3] Maintenance Contract: The new gamma knife installed in April 2014 includes a one year warranty. The new maintenance agreement began in April of 2015. The monthly payment has remained at $20,000 and is in effect for 5 years. [4] Guarantee of Lease Obligations: USNC is a 20% guarantor on NeuroPartners, LLC’s seven-year lease with respect to the gamma knife equipment and certain leasehold improvements at the Southern California Regional Gamma Knife Center at SARH in Upland, California, where the equipment is located. The outstanding balance on the lease obligations was $970,000 and $1,660,000 at December 31, 2015 and 2014, respectively. In February of 2016, NeuroPartners negotiated a new lease to fund the reloading of cobalt and the necessary construction to do so. The new lease of $1,663,000 includes the balance of the lease obligations. This lease will be paid over 60 months. The first payment is due on April 1, 2016. USNC is also a guarantor for a maximum of $1,433,000, approximately 25% of the original lease amount, on FOP’s LLC’s seven-year lease. It is a guarantor jointly with most of the other members (except USNC who is not a named guarantor) of FOP. The outstanding balance on the lease obligation was $2,502,000 and $3,398,000 at December 31, 2015 and 2014, respectively. The Company expects any potential obligations from these guarantees to be reduced by the recoveries of the respective collateral and expects any liabilities arising from these guarantees to be insignificant. [5] Guarantee of Mortgages: USN was a 20% guarantor on FOPRE’s ten-year mortgage. This mortgage had an original balance of $1,534,000 and was secured by the commercial condominiums in which FOP operates. In December of 2015, FOPRE sold the building and repaid the mortgage with the sales proceeds. USNC is a 10% guarantor on 50% of the outstanding balance of Boca West IMP’s ten-year mortgage. This mortgage had an original balance of $3,000,000 and is secured by the medical office building in which BOP operates. The outstanding balance on the mortgage is $2,632,000 and $2,730,000 at December 31, 2015 and 2014, respectively. The Company expects any potential obligations from this guarantee to be reduced by the recovery of the real estate collateral and expects any amounts arising from this guarantee to be insignificant. [6] Product liability: Although USN does not directly provide medical services, it has obtained professional medical liability insurance, and has general liability insurance as well. USN’s professional medical liability and general liability policies have limits of $3 million each. The Company believes that its insurance is adequate for providing treatment facilities and non-medical services, although there can be no assurance that the coverage limits of such insurance will be adequate or that coverage will not be reduced or become unavailable in the future.

Employees' IRA Plans

Employees' IRA Plans	12 Months Ended
	Dec. 31, 2015
Employees' IRA Plans [Abstract]
Employees' IRA Plans	Note J - Employees' IRA Plans The Company has established a Company IRA covering all employees. The plan allows participants to make pre-tax contributions and the Company may, at its discretion, match certain percentages of the employee contribution. Amounts contributed to the plan are deposited into a trust fund administered by independent trustees. The Company made a discretionary matching IRA contribution of $14,000 for both 2015 and 2014.

The Company and its Significa17

The Company and its Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
The Company and its Significant Accounting Policies [Abstract]
Basis of presentation and consolidation	[1] Basis of presentation and consolidation: The consolidated financial statements include the accounts of Holdings and its wholly-owned subsidiaries, USN, USNC and US NeuroSurgical Physics, Inc.. All significant intercompany balances and transactions have been eliminated in consolidation.
Cash and cash equivalents	[2] Cash and cash equivalents: The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.
Investments in unconsolidated entities	[3] Investments in unconsolidated entities: The Company accounts for its investments in unconsolidated entities by the equity method. The Company records its share of such earnings (loss) in the Consolidated Statement of Operations as “Income (loss) from investments in unconsolidated entities”. The carrying value of the Company’s investments in unconsolidated entities is recorded in the Consolidated Balance Sheets. The Company records losses of the unconsolidated entities only to the extent of the Company’s interest in and advances to the entities. As such, the recorded balance of Corona Gamma Knife, LLC and NeuroPartners, LLC have been taken to zero.
Revenue recognition	[4] Revenue recognition: The Company’s agreement with NYU is an operating lease, and patient revenue from the use of the gamma knife is lease income. There are no minimum lease payments from NYU. The NYU agreement provides for contingent rental income based on a tiered fee schedule related to the number of patient procedures and associated thresholds. The Company recognizes the contingent rental income on a systematic basis using an average fee per procedure calculated by estimating the expected number of procedures per contract year which runs from November 1, to the following October 31. Any amounts received in excess of the average fee are considered deferred revenue. At the end of each reporting period, the Company reviews its estimated revenue for the contract year and adjusts revenue for any material changes in the estimate. At the end of the contract year, the revenue is adjusted to the actual amount received.
Long-lived assets	[5] Long-lived assets: The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Depreciation and amortization	[6] Depreciation and amortization: The gamma knife is being depreciated on the straight-line method over an estimated useful life of 7 years. Leasehold improvements are being amortized on the straight-line method over 7 years, the shorter of useful life, or the life of the NYU Agreement. Office furniture and computers are being depreciated on the straight-line method over their estimated useful lives ranging from 3 to 7 years. Depreciation expense for 2015 and 2014 was $622,000 and $475,000 respectively. Amortization expense for 2015 and 2014 was $313,000 and $197,000 respectively.
Capital leases	[7] Capital leases: Capital lease obligations are amortized ratably over the original term of the lease agreement, beginning with the earlier of the date the leased assets are placed in service or the effective date of the lease as defined in the lease agreement.
Guarantees	[8] Guarantees: The Company recognizes a liability at the fair value of the obligation at the inception of a financial guarantee contract. The initial liability is subsequently reduced as the Company is released from exposure under the guarantee. If it becomes probable that the Company will have to perform on a guarantee, a separate liability is accrued if it is reasonably estimable, based on the facts and circumstances at that time. The Company reverses the fair value liability only when there is no further exposure under the guarantee.
Income taxes	[9] Income taxes: Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce tax assets to amounts more likely than not to be realized. The Company has adopted the accounting provisions for Accounting for Uncertainty in Income Taxes
Earnings per share	[10] Earnings per share: Earnings per share are computed by dividing earnings available to common stockholders by the weighted average shares outstanding for the period. There were no common stock equivalents during 2015 and 2014, and therefore, no potential dilution for the periods presented.
Advertising costs	[11] Advertising costs: The Company follows the policy of charging the costs of advertising to expense as incurred. There were no advertising costs in 2015 and 2014.
Allowance for doubtful accounts	[12] Allowance for doubtful accounts: The Company evaluates each of its accounts receivable individually and provides a charge to income that is appropriate, in the opinion of management, to absorb probable credit losses. The Company considers all accounts receivable to be collectible at December 31, 2015 and 2014.
Estimates and assumptions	[13] Estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair values of financial instruments	[14] Fair values of financial instruments: The estimated fair value of financial instruments has been determined based on available market information and appropriate valuation methodologies. The carrying amounts of cash and cash equivalents, accounts receivable, other current assets, due from or to related parties, and accounts payable approximate fair value at December 31, 2015 and 2014 because of the short maturity of these financial instruments. The carrying values of the notes receivable and the obligations under capital leases, approximate fair value because the interest rates on these instruments approximate the market rates at December 31, 2015 and 2014.
Credit risk	[15] Credit risk: At times, the Company may have cash and cash equivalents at a financial institution in excess of insured limits. The Company places its cash and cash equivalents with high credit quality financial institutions whose credit ratings are monitored by management to minimize credit risk. Accounts receivable consist primarily of amounts due from the medical centers. Historically, credit losses on accounts receivable have not been significant. At December 31, 2015 and 2014, substantially all of the Company’s accounts receivable were due from one customer, NYU.
Asset retirement obligations	[16] Asset retirement obligations: The Company records liabilities for legal obligations associated with the retirement of tangible long-lived assets based on the estimated future cost of asset retirement obligations discounted to present value, and records a corresponding asset and liability on its consolidated balance sheets. The values ultimately derived are based on many significant estimates, including future decommissioning costs, inflation, cost of capital, and market risk premiums. The nature of these estimates requires the Company to make judgments based on historical experience and future expectations. Revisions to the estimates may be required based on such things as changes to cost estimates or the timing of future cash outlays. Any such changes that result in upward or downward revisions in the estimated obligation will result in an adjustment to the related capitalized asset and corresponding liability on a prospective basis.

Investment in Unconsolidated 18

Investment in Unconsolidated Entities (Tables)	12 Months Ended
	Dec. 31, 2015
Neuro Partners LLC and CGK [Member]
Schedule of Equity Method Investments [Line Items]
Summarized Financial Information	The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK: Neuro Partners LLC and CGK Combined Condensed Income Statement Information Year Ended December 31, 2015 2014 Patient revenue $ 912,000 $ 1,223,000 Net (loss) income $ (184,000 ) $ 74,000 USNC's equity in (loss) income of Neuro Partners LLC and CGK $ (84,000 ) $ 14,000 Neuro Partners LLC and CGK Combined Condensed Balance Sheet Information December 31, 2015 2014 Current assets $ 66,000 $ 92,000 Noncurrent assets 394,000 991,000 Total assets $ 460,000 $ 1,083,000 Current liabilities $ 1,359,000 $ 829,000 Noncurrent liabilities - 969,000 Equity (899,000 ) (715,000 ) Total liabilities and equity $ 460,000 $ 1,083,000
FOP and FOPRE [Member]
Schedule of Equity Method Investments [Line Items]
Summarized Financial Information	The following tables present the aggregation of summarized financial information of FOP and FOPRE: FOP and FOPRE Combined Condensed Income Statement Information Year Ended December 31, 2015 2014 Revenue $ 3,157,000 $ 2,631,000 Net income $ 1,344,000 $ 197,000 USNC's equity in income of FOP and FOPRE $ 323,000 $ 39,000 FOP and FOPRE Combined Condensed Balance Sheet Information December 31, 2015 2014 Current assets $ 1,024,000 $ 606,000 Noncurrent assets 3,066,000 5,070,000 Total assets $ 4,090,000 $ 5,676,000 Current liabilities $ 1,848,000 $ 858,000 Noncurrent liabilities 1,529,000 3,947,000 Equity 713,000 871,000 Total liabilities and equity $ 4,090,000 $ 5,676,000
BOP and BOPRE [Member]
Schedule of Equity Method Investments [Line Items]
Summarized Financial Information	The following tables present the summarized financial information of BOP and BOPRE: BOP Condensed Income Statement Information Year Ended December 31, 2014 Patient revenue $ 115,000 Net loss $ (108,000 ) USNC's equity in loss $ (12,000 ) BOPRE Condensed Income Statement Information Years Ended December 31, 2015 2014 Rental Income $ 3,000 $ - Net income (loss) $ 3,000 $ (4,000 ) USNC's equity in loss $ - $ - BOPRE Condensed Balance Sheet Information December 31, 2015 2014 Current assets $ 40,000 $ 61,000 Noncurrent assets 837,000 786,000 Total assets $ 877,000 $ 847,000 Current liabilities $ - $ - Noncurrent liabilities - - Equity 877,000 847,000 Total liabilities and equity $ 877,000 $ 847,000
Broward Oncology Partners, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Summarized Financial Information	Broward Oncology Partners, LLC Condensed Income Statement Information Year Ended December 31, Patient revenue $ 505,000 Net income (loss) $ 255,000 USNC's equity in income (loss) of Broward Oncology Partners $ 32,000

Obligation Under Capital Lease

Obligation Under Capital Lease (Tables)	12 Months Ended
	Dec. 31, 2015
Obligation Under Capital Lease [Abstract]
Obligations Under Capital Leases	The obligations under the capital leases are as follows: December 31, 2015 2014 Capital leases - Gamma Knife $ 3,811,000 $ 4,659,000 Less current portion (866,000 ) (821,000 ) $ 2,945,000 $ 3,838,000
Analysis of Leased Assets Included in Property and Equipment	The following is an analysis of the leased assets included in property and equipment: December 31, 2015 2014 Capitalized costs $ 4,303,000 $ 4,303,000 Less - accumulated depreciation (1,076,000 ) (461,000 ) Capitalized lease equipment and improvements- reported as property and equipment - net $ 3,227,000 $ 3,842,000
Future Payment on Equipment Leases and Loans	Future payments as of December 31, 2015 on the equipment leases and loans are as follows: Year Ending December 31, 2016 $ 1,019,000 2017 931,000 2018 931,000 2019 931,000 2020 388,000 4,200,000 Less interest (389,000 ) Present value of net minimum obligation $ 3,811,000

Asset Retirement Obligations (T

Asset Retirement Obligations (Tables)	12 Months Ended
	Dec. 31, 2015
Asset Retirement Obligations [Abstract]
Asset Retirement Obligations	When the NYU agreement was finalized, the Company estimated the cost to remove the gamma knife at the end of the agreement to be approximately $620,000. The estimated present value of this liability is $466,000 at December 31, 2015 and $431,000 at December 31, 2014. 2015 2014 Asset retirement obligations, start of year $ 431,000 $ - Asset retirement obligation for new gamma knife 431,000 Accretion of liability 35,000 - Asset retirement of obligations, end of the year $ 466,000 $ 431,000

Taxes (Tables)

Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Taxes [Abstract]
Reconciliation of Tax Provision	A reconciliation of the tax provision calculated at the statutory federal income tax rate with amounts reported follows: Year Ended December 31, 2015 2014 Income tax at the federal statutory rate $ 220,000 $ 273,000 State income tax, net of federal taxes 21,000 26,000 Permanent differences 14,000 11,000 Other (3,000 ) (16,000 ) Change in valuation allowance - (52,000 ) Income tax (benefit) provision $ 252,000 $ 242,000
Deferred Tax Assets and Liabilities	Items which give rise to deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax asset: Net operating loss $ 463,000 $ 667,000 Basis difference in unconsolidated entities 32,000 - 495,000 667,000 Deferred tax liability: Basis difference in unconsolidated entities - (61,000 ) Deferred gain on disposal of gamma knife (716,000 ) (716,000 ) Excess of depreciation over book depreciation (82,000 ) (40,000 ) Net effect of conversion from the accrual basis of accounting to the cash basis of accounting for tax purposes primarily related to accounts receivable, prepaid expense, deferred revenue, and accounts payable (191,000 ) (92,000 ) Net deferred tax liability $ (494,000 ) $ (242,000 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Future Minimum Rental Payments Under Operating Leases	At December 31, 2015, the annual future minimum rental payments under operating leases are as follows: Year Ending December 31, 2016 $ 42,000 2017 43,000 2018 11,000 $ 96,000

Organization and Business (Deta

Organization and Business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2015	Dec. 31, 2014	Jan. 31, 2013	Dec. 31, 2011	Dec. 31, 2010
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated entities		$ 364,000	$ 323,000
Florida Oncology Partners, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage in venture						24.00%
Boca Oncology Partners, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage in venture	11.25%				22.50%
Percentage of ownership sold	50.00%
Broward Oncology Partners, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage in venture				12.50%
Investment in unconsolidated entities				$ 50,000

The Company and its Significa24

The Company and its Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash and cash equivalents [Abstract]
Maximum maturity period for debt instruments to be considered cash equivalent	3 months
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 622,000	$ 475,000
Amortization expense	$ 313,000	$ 197,000
Earnings per share [Abstract]
Common stock equivalents (in shares)	0	0
Potential dilution shares (in shares)	0	0
Advertising costs [Abstract]
Advertising cost	$ 0	$ 0
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 364,000	$ 323,000
Gamma Knives [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Office Furniture and Computer [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Office Furniture and Computer [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Corona Gamma Knife, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 0
Neuro Partners, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 0

Investment in Unconsolidated 25

Investment in Unconsolidated Entities (Details)	Feb. 28, 2014USD ($)	Dec. 31, 2015USD ($)ft²Member	Dec. 31, 2014USD ($)	Jan. 31, 2013USD ($)	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2011USD ($)	Sep. 30, 2010USD ($)
The Southern California Regional Gamma Knife Center [Abstract]
Renovation installation and operation agreement period		14 years
Condensed Income Statement Information [Abstract]
Revenue		$ 2,971,000	$ 2,607,000
USNC's equity in (loss) income of investment in unconsolidated entities		285,000	14,000
Florida Oncology Partners [Abstract]
Recorded investments		364,000	323,000
Due from related parties		21,000	8,000
Boca Oncology Partners [Abstract]
Investment in unconsolidated entities		364,000	323,000
Proceeds from short-term loans		$ 0	462,000
Boca Oncology Partners, LLC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		11.25%
Condensed Income Statement Information [Abstract]
Revenue			115,000
Net (loss) income			(108,000)
USNC's equity in (loss) income of investment in unconsolidated entities			(12,000)
Boca Oncology Partners [Abstract]
Area of real estate property | ft²		6,000
Gain from sale of interests	$ 204,000
Amount loaned to related parties		$ 56,250
Debt maturity period		5 years
Company loan interest rate		7.00%
Number of members who provided short term loans | Member		3
Proceeds from short-term loans	$ 462,000
Accrued interest		$ 26,000
Boca Oncology Partners, LLC [Member] | USNC [Member]
Boca Oncology Partners [Abstract]
Amount loaned to related parties		$ 28,000
Boca Oncology Partners RE, LLC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		15.40%
Condensed Income Statement Information [Abstract]
Rental income		$ 3,000	0
Net (loss) income		3,000	(4,000)
USNC's equity in (loss) income of investment in unconsolidated entities		0	0
Condensed Balance Sheet Information [Abstract]
Current assets		40,000	61,000
Noncurrent assets		837,000	786,000
Total assets		877,000	847,000
Current liabilities		0	0
Noncurrent liabilities		0	0
Equity		877,000	847,000
Total liabilities and equity		877,000	847,000
Florida Oncology Partners [Abstract]
Recorded investments		$ 139,000	134,000
Ownership percentage by outside investors		31.50%
Boca Oncology Partners [Abstract]
Percentage of interest in medical office building		20.00%
Investment in unconsolidated entities		$ 139,000	134,000
BOP and BOPRE [Member]
Florida Oncology Partners [Abstract]
Ownership percentage by outside investors		88.75%
Boca Oncology Partners [Abstract]
Area of real estate property | ft²		32,000
Additional investor purchased		50.00%
BOP and BOPRE [Member] | USNC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage							22.50%
Florida Oncology Partners [Abstract]
Recorded investments							$ 225,000
Boca Oncology Partners [Abstract]
Investment in unconsolidated entities							$ 225,000
Boca West IMP [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		23.75%				3.75%
BOP and USNC's [Member]
Boca Oncology Partners [Abstract]
Reduced ownership percentage		15.40%
CGK [Member] | USNC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage					39.00%		44.00%
Initial ownership percentage		27.00%
Neuro Partners LLC [Member] | USNC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		20.00%
FOP and FOPRE [Member]
Condensed Income Statement Information [Abstract]
Revenue		$ 3,157,000	2,631,000
Net (loss) income		1,344,000	197,000
USNC's equity in (loss) income of investment in unconsolidated entities		323,000	39,000
Condensed Balance Sheet Information [Abstract]
Current assets		1,024,000	606,000
Noncurrent assets		3,066,000	5,070,000
Total assets		4,090,000	5,676,000
Current liabilities		1,848,000	858,000
Noncurrent liabilities		1,529,000	3,947,000
Equity		713,000	871,000
Total liabilities and equity		4,090,000	5,676,000
Florida Oncology Partners [Abstract]
Recorded investments		$ 225,000	190,000
Ownership percentage by outside investors		76.00%
Due from related parties		$ 21,000	8,000
Gain on sale of building		577,000
Boca Oncology Partners [Abstract]
Investment in unconsolidated entities		$ 225,000	190,000
FOP and FOPRE [Member] | USNC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage		24.00%						20.00%
Florida Oncology Partners [Abstract]
Recorded investments								$ 200,000
Boca Oncology Partners [Abstract]
Investment in unconsolidated entities								$ 200,000
Neuro Partners LLC and CGK [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Losses against outstanding receivables		$ 62,000	45,000
Condensed Income Statement Information [Abstract]
Revenue		912,000	1,223,000
Net (loss) income		(184,000)	74,000
USNC's equity in (loss) income of investment in unconsolidated entities		(84,000)	14,000
Condensed Balance Sheet Information [Abstract]
Current assets		66,000	92,000
Noncurrent assets		394,000	991,000
Total assets		460,000	1,083,000
Current liabilities		1,359,000	829,000
Noncurrent liabilities		0	969,000
Equity		(899,000)	(715,000)
Total liabilities and equity		460,000	1,083,000
Boca Oncology Partners [Abstract]
Losses against outstanding receivables		$ 62,000	45,000
Broward Oncology Partners, LLC [Member]
The Southern California Regional Gamma Knife Center [Abstract]
Ownership percentage				12.50%
Condensed Income Statement Information [Abstract]
Revenue			505,000
Net (loss) income			255,000
USNC's equity in (loss) income of investment in unconsolidated entities			$ 32,000
Florida Oncology Partners [Abstract]
Recorded investments				$ 50,000
Boca Oncology Partners [Abstract]
Investment in unconsolidated entities				$ 50,000

Agreement with New York Unive26

Agreement with New York University on Behalf of New York University Medical Center (NYU) (Details) - USD ($)	Sep. 01, 2014	Oct. 31, 2012	Nov. 30, 1996	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2008	Nov. 01, 2014
Agreement With New York University on Behalf of New York University Medical Center (NYU) [Abstract]
Term of equipment agreement with NYC			7 years
Option to extend agreement term			3 years
Patient revenue derived from the NYC				$ 2,944,000	$ 2,607,000
Extension of agreement							12 years
Cost of new equipment installed						$ 3,742,000	$ 3,742,000
Equipment financed term						7 years	7 years
Emergency removal cost		$ 525,000
Insurance coverage		$ 930,000
First lease term				6 years	6 years
Commitment for lease financing for replacement equipment and restoration				$ 4,700,000	$ 4,700,000
First payment due	$ 78,000				78,000
Interest on lease	$ 18,000				18,000
Second lease term				2 years
Lease amount for cost of construction				$ 250,000	250,000
First lease payment due for the cost of construction					$ 12,468			$ 12,000

Obligation Under Capital Leas27

Obligation Under Capital Lease (Details) - USD ($)	Oct. 31, 2012	Mar. 31, 2009	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2009	Dec. 31, 2008
Capital Lease [Abstract]
Equipment financed term						7 years	7 years
Removal costs of the old equipment	$ 525,000
Lease amount for cost of construction			$ 250,000	$ 250,000
Perfexion Gamma Knife [Member]
Capital Lease [Abstract]
Equipment financed term		7 years
Capital lease asset under construction		$ 3,742,000	4,303,000	$ 4,303,000
Monthly payment for capital lease		$ 63,000	389,000
Implicit interest rate		11.00%
Modified equipment capitalized cost under agreement					$ 4,700,000
Modified equipment financed term, maximum				24 months	72 months
Removal costs of the old equipment					$ 525,000
Lease amount for cost of construction				$ 250,000
Depreciation expense			615,000	461,000
Capitalized interest				51,000
Obligation under capital leases [Abstract]
Capital leases- Gamma Knife			3,811,000	4,659,000
Less current portion			(866,000)	(821,000)
Capital lease obligations, noncurrent			2,945,000	3,838,000
Analysis of leased assets included in property and equipment [Abstract]
Capitalized costs		$ 3,742,000	4,303,000	4,303,000
Less - accumulated depreciation			(1,076,000)	(461,000)
Capitalized lease equipment and improvements-reported as property and equipment - net			3,227,000	$ 3,842,000
Future payment on equipment leases and loans [Abstract]
2,016			1,019,000
2,017			931,000
2,018			931,000
2,019			931,000
2,020			388,000
Total			4,200,000
Less interest		$ (63,000)	(389,000)
Present value of net minimum obligation			$ 3,811,000

Asset Retirement Obligations (D

Asset Retirement Obligations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Asset Retirement Obligations [Abstract]
Estimated cost to remove the gamma knife agreement	$ 620,000
Asset Retirement Obligations Roll Forward [Abstract]
Asset retirement obligations, start of year	431,000	$ 0
Asset retirement obligation for new gamma knife	0	431,000
Accretion of liability	35,000	0
Asset retirement of obligations, end of the year	$ 466,000	$ 431,000

Taxes (Details)

Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Tax Provision (Benefit)
Income tax at the federal statutory rate	$ 220,000	$ 273,000
State income tax, net of federal taxes	21,000	26,000
Permanent differences	14,000	11,000
Other	(3,000)	(16,000)
Change in valuation allowance	0	(52,000)
Income tax (benefit) provision	252,000	242,000
Deferred tax asset [Abstract]
Net operating loss	463,000	667,000
Basis difference in unconsolidated entities	32,000	0
Deferred tax assets, gross	495,000	667,000
Deferred tax liability [Abstract]
Basis difference in unconsolidated entities	0	(61,000)
Deferred gain on disposal of gamma knife	(716,000)	(716,000)
Excess of depreciation over book depreciation	(82,000)	(40,000)
Net effect of conversion from the accrual basis of accounting to the cash basis of accounting for tax purposes primarily related to accounts receivable, prepaid expense, deferred revenue, and accounts payable	(191,000)	(92,000)
Net deferred tax liability	(494,000)	$ (242,000)
Loss Carryforwards Expiration [Abstract]
Operating loss carryforwards	$ 1,239,000

Commitments and Contingencies30

Commitments and Contingencies (Details) - USD ($)	Sep. 01, 2014	Feb. 29, 2016	Apr. 30, 2015	Apr. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2008	Nov. 01, 2014
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016					$ 42,000
2,017					43,000
2,018					11,000
Total future rental payments					96,000
Rent expense					$ 41,000	$ 43,000
Gamma Knives [Abstract]
Cost of new equipment installed							$ 3,742,000	$ 3,742,000
Equipment financed term							7 years	7 years
First lease term					6 years	6 years
Commitment for lease financing for replacement equipment and restoration					$ 4,700,000	$ 4,700,000
First payment due	$ 78,000					78,000
Interest on lease	$ 18,000					18,000
Lease amount for cost of construction					$ 250,000	250,000
First lease payment due for the cost of construction						12,468			$ 12,000
Number of years cobalt should be reloaded for each gamma knife, minimum					5 years
Number of years cobalt should be reloaded for each gamma knife, maximum					10 years
Maintenance Contract [Abstract]
Maintenance agreement			5 years
Monthly maintenance agreement cost			$ 20,000
Warrant term of maintenance agreement				1 year
Product Liability [Abstract]
Professional medical and general liability policies limits					$ 3,000,000
FOPRE [Member]
Guarantee of Mortgages [Abstract]
Share of guarantee in mortgage					20.00%
Mortgage term of guarantee					10 years
Original balance of mortgage					$ 1,534,000
Neuro Partners, LLC [Member]
Loss Contingencies [Line Items]
Share of guarantee in lease obligation					20.00%
Operating lease payable					$ 970,000	1,660,000
Lease term					7 years
Neuro Partners, LLC [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Operating lease payable		$ 1,663,000
Lease term		60 months
Florida Oncology Partners R E LLC [Member]
Loss Contingencies [Line Items]
Share of guarantee in lease obligation					25.00%
Operating lease payable					$ 2,502,000	3,398,000
Lease term					7 years
Maximum guarantee					$ 1,433,000
Boca West IMP [Member]
Guarantee of Mortgages [Abstract]
Share of guarantee in mortgage					10.00%
Mortgage term of guarantee					10 years
Original balance of mortgage					$ 3,000,000
Outstanding balance on mortgage					$ 2,632,000	$ 2,730,000
Share of guarantee in outstanding mortgage					50.00%

Employees' IRA Plans (Details)

Employees' IRA Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employees' IRA Plans [Abstract]
Employer discretionary contribution amount	$ 14,000	$ 14,000